Abstract: The present invention is directed to peptidylglycine alpha-amidating monooxygenase (PAM) for use as a medicament and the treatment of a subject, wherein said treatment comprises: reducing the potential or risk for a disease or disorder, and/or reducing the occurrence of a disease or disorder, and/or reducing the severity of a disease or disorder.
Abstract: The present invention is directed to a method for diagnosis or prognosis of a disease in a subject and/or predicting a risk of getting a disease or adverse event in a subject and/or monitoring a disease or adverse event in a subject by determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or its isoforms and/or fragments thereof in a sample of bodily fluid of said subject.
© 2025 Justia
